Comment & Response
March 2015

Comparative Effectiveness of Bevacizumab and Ranibizumab in the Comparison of Age-Related Macular Degeneration Treatments Trials

Author Affiliations
  • 1Health Technology Assessment Unit, Area Vasta Toscana Centro, Regional Health Service, Firenze, Italy

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Ophthalmol. 2015;133(3):363-364. doi:10.1001/jamaophthalmol.2014.4642

To the Editor In 2012, Martin et al1 published the results at 2 years of the Comparison of Age-Related Macular Degeneration Treatments Trials and found a nonsignificant difference between bevacizumab and ranibizumab according to the continuous end point of the change in letters of visual acuity (mean difference for bevacizumab vs ranibizumab, −1.4 letters; 95% CI, −3.7 to +0.8 letters; P = .21). More recently, Ying et al2 carried out a multivariate analysis of the same study data in which the bevacizumab group was shown to have higher odds of losing 15 or more letters than the ranibizumab group (odds ratio, 1.83; 95% CI, 1.07 to 3.14; P = .03).

First Page Preview View Large
First page PDF preview
First page PDF preview